These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
1076 related items for PubMed ID: 32475726
21. Cytology and human papillomavirus screening test results associated with 2827 histopathologic diagnoses of cervical intraepithelial neoplasia 2/3. Zhao C, Amin M, Weng B, Chen X, Kanbour-Shakir A, Austin RM. Arch Pathol Lab Med; 2013 Jul; 137(7):942-7. PubMed ID: 23050808 [Abstract] [Full Text] [Related]
25. High-Risk Human Papillomavirus Testing, Genotyping, and Histopathologic Follow-up in Women With Abnormal Glandular Cells on Papanicolaou Tests. Zuo T, Levi AW, Lin Q, Abi-Raad R, Adeniran AJ, Cai G. Am J Clin Pathol; 2021 Sep 08; 156(4):569-576. PubMed ID: 33728437 [Abstract] [Full Text] [Related]
26. Low-grade squamous intraepithelial lesion, cannot rule out high-grade lesion: Diagnosis, histological outcomes and human papillomavirus results. Segura SE, Ramos-Rivera G, Hakima L, Suhrland M, Khader S. Cytopathology; 2019 Jan 08; 30(1):99-104. PubMed ID: 30187975 [Abstract] [Full Text] [Related]
27. Three-year longitudinal data on the clinical performance of the Abbott RealTime High Risk HPV test in a cervical cancer screening setting. Poljak M, Oštrbenk A, Seme K, Šterbenc A, Jančar N, Vrtačnik Bokal E. J Clin Virol; 2016 Mar 08; 76 Suppl 1():S29-S39. PubMed ID: 26643051 [Abstract] [Full Text] [Related]
28. Prevalence of high-risk human papillomavirus in women with abnormal and normal vaginal ThinPrep Papanicolaou cytology. Bansal M, Zhao C. J Low Genit Tract Dis; 2011 Apr 08; 15(2):105-9. PubMed ID: 21317806 [Abstract] [Full Text] [Related]
29. Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results. Manos MM, Kinney WK, Hurley LB, Sherman ME, Shieh-Ngai J, Kurman RJ, Ransley JE, Fetterman BJ, Hartinger JS, McIntosh KM, Pawlick GF, Hiatt RA. JAMA; 1999 May 05; 281(17):1605-10. PubMed ID: 10235153 [Abstract] [Full Text] [Related]
30. The reporting rates of high-grade squamous intraepithelial lesions and their human papillomavirus testing and histologic follow-up results: A comparison between ThinPrep and SurePath preparations. Sinclair WD, Gibbons-Fideler IS, Shen R, Li Z. Diagn Cytopathol; 2021 Aug 05; 49(8):959-963. PubMed ID: 33991062 [Abstract] [Full Text] [Related]
31. [Clinical value of p16INK4a immunocytochemistry in cervical cancer screening]. Song FB, Du H, Xiao AM, Wang C, Huang X, Yan PS, Liu ZH, Qu XF, Belinson JEROMEL, Wu RF. Zhonghua Fu Chan Ke Za Zhi; 2020 Nov 25; 55(11):784-790. PubMed ID: 33228350 [Abstract] [Full Text] [Related]
32. Three-year risk of high-grade CIN for women aged 30 years or older who undergo baseline Pap cytology and HPV co-screening. Guo M, Khanna A, Wang J, Dawlett MA, Kologinczak TL, Lyons GR, Bassett RL, Sneige N, Gong Y, Bevers TB. Cancer Cytopathol; 2017 Aug 25; 125(8):644-651. PubMed ID: 28498639 [Abstract] [Full Text] [Related]
39. Experience of Combined Liquid Based Cervical Cytology and High-Risk HPV mRNA for Cervical Cancer Screening in Thammasat University Hospital. Muangto T, Chanthasenanont A, Lertvutivivat S, Nanthakomon T, Pongrojpaw D, Bhamarapravatana K, Suwannarurk K. Asian Pac J Cancer Prev; 2016 Aug 25; 17(9):4409-4413. PubMed ID: 27797253 [Abstract] [Full Text] [Related]